Preparation method of chiral arylamine, heteroarylamine and alkylamine
By using potential ketones and inorganic ammonia in the amine dehydrogenase catalytic system, combining deep eutectic solvents and glucose dehydrogenase regeneration system, the problem of narrow amine dehydrogenase substrate spectrum is solved, achieving high efficiency and green The synthesis of chiral aryl amines, heteroaryl amines and alkyl amines has high yields and good stereoselectivity.
Patent Information
- Application Number
- CN202411433996.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-15
- Publication Date
- 2024-11-26
AI Technical Summary
In the prior art, the substrate spectrum of amine dehydrogenase is relatively narrow, making it difficult to catalyze the efficient reduction amination of various aryl ketones, heteroaryl ketones or alkyl ketones, and it is difficult to obtain high concentrations in pure aqueous reaction systems. Higher yields of substrates.
采用相对应的潜手性酮作为原料,利用无机氨作为胺供体,水为主溶剂结合助溶剂,胺脱氢酶为生物催化剂,NADH为辅酶,偶联葡萄糖与葡萄糖脱氢酶为辅酶再生体系,通过深共熔溶剂或有机溶剂提高反应效率,优化反应条件如温度和pH值,突变胺脱氢酶以提高催化活性。
Achieved a one-step reduction and amination under mild conditions to produce optically pure chiral aryl amines, heteroaryl amines, and alkyl amines. The by-product is only water, the process route is simple, the yield is high, the advantages of green synthesis and high three-dimensional Selectivity (ee value up to 99%).
Smart Images

Figure CN119020446A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of chemical synthesis, and in particular relates to a method for preparing chiral arylamine, heteroarylamine and alkylamine. Background Art
[0002] Optically pure chiral arylamines, heteroarylamines, and alkylamines are special core structural motifs in organic chemistry, drugs, and natural products, and are synthetic targets with many potential applications, especially as active pharmaceutical ingredients. Therefore, the development of efficient and asymmetric methods for the synthesis of these unique chiral arylamines, heteroarylamines, and alkylamines has attracted considerable attention in the industry.
[0003] Amine dehydrogenase can use cheap inorganic ammonia as an amino donor to catalyze the one-step reductive amination of potential chiral ketones to generate optically pure chiral amines. The only byproduct is water, which is a green and efficient catalytic method. However, the substrate spectrum of amine dehydrogenase is relatively narrow, and it can only catalyze aryl ketones, heteroaryl ketones or alkyl ketones. There are very few amine dehydrogenases that are compatible with aryl ketones, heteroaryl ketones, and alkyl ketones. In addition, due to the poor water solubility of amine dehydrogenase substrates, it is often difficult to catalyze high-concentration substrates in a pure water phase reaction system to obtain a high yield. Summary of the invention
[0004] In order to solve the problems existing in the prior art, the present invention provides an asymmetric biocatalytic synthesis method for chiral aromatic amines, heteroaromatic amines and alkylamine compounds, which belongs to green catalytic asymmetric synthesis technology.
[0005] In order to achieve the above object, the technical solution adopted by the present invention is as follows:
[0006] The present invention provides a method for preparing chiral arylamine, heteroarylamine and alkylamine, comprising the following steps:
[0007] The corresponding prochiral ketone is used as a raw material, inorganic ammonia is used as an amine donor, water is used as a main solvent and a cosolvent is used to form a solvent system, amine dehydrogenase is used as a biocatalyst, NADH is used as a coenzyme, and coupled glucose and glucose dehydrogenase are used as a coenzyme regeneration system to reduce and aminize the ketone into chiral arylamine, heteroarylamine, and alkylamine.
[0008] The reaction formula is as follows:
[0009]
[0010] in:
[0011] R1 represents any one of aryl, heteroaryl, and alkyl;
[0012] R2 represents any alkyl group having 3 or less carbon atoms;
[0013] When R1 is an alkyl group, it is the same as or different from R2;
[0014] The co-solvent is a deep eutectic solvent, an organic solvent or an ionic liquid.
[0015] As a preferred embodiment, the aryl group includes phenyl or benzyl, or alkyl-substituted phenyl or benzyl, or halogen-substituted phenyl or benzyl, or nitro-substituted phenyl or benzyl, or alkylphenyl, wherein the alkyl group in the alkylphenyl has 2-4 carbon atoms;
[0016] The heteroaryl groups include pyridine, pyrimidine, thiazole, thiophene, furan, and N-substituted indole;
[0017] The carbon number of the alkyl group in R1 is 1-20.
[0018] As a preferred embodiment, the concentration of the prochiral ketone is 0.5-2 mol / L.
[0019] As a preferred embodiment, the deep eutectic solvent comprises DESs constructed with methyl trioctyl ammonium chloride and fatty acid in a molar ratio of 1:(0.5-2);
[0020] The organic solvent is selected from heptane, ethylene glycol, DMSO, acetonitrile, n-hexane, cyclohexane or methyl tert-butyl ether;
[0021] The ionic liquid is an imidazole ionic liquid, preferably 1-butyl-3-methylimidazolium hexafluorophosphate, 1-butyl-3-methylimidazolium di(trifluoromethylsulfonyl)imide, 1-butyl-3-methylimidazolium dinitrile amine salt or 1-butyl-3-methylimidazolium bromide;
[0022] Preferably, the fatty acids include saturated fatty acids and unsaturated fatty acids; the saturated fatty acids are selected from 7-22C fatty acids, such as heptanoic acid, octanoic acid, nonanoic acid and decanoic acid; the unsaturated fatty acids are selected from oleic acid or linolenic acid.
[0023] As a preferred embodiment, the concentration of the deep eutectic solvent is 1-50% (v / v); preferably, the concentration of the deep eutectic solvent is 20% (v / v); and / or
[0024] The deep eutectic solvent is constructed from methyltrioctylammonium chloride and oleic acid in a molar ratio of 1:2.
[0025] As a preferred embodiment, the amino acid sequence of the amine dehydrogenase is SEQ ID No. 2 in the sequence list; or
[0026] The amino acid sequence of the amine dehydrogenase is mutated based on SEQ ID No. 2 in the sequence list, and the mutation includes at least one of the following (1)-(3):
[0027] (1) Position 134 mutated from V to A or G;
[0028] (2) position 299 mutated from V to A or G;
[0029] (3) position 300 mutated from S to G, A, V, or F;
[0030] Preferably, the mutation is any one of (M1)-(M8) in Table 1 below;
[0031] Most preferably, the amino acid sequence of the amine dehydrogenase is based on SEQ ID No. 2 in the sequence listing, with the 134th position mutated from V to A, the 299th position mutated from V to A, and the 300th amino acid residue mutated from S to G.
[0032] As a preferred embodiment, the nucleotide sequence of the amine dehydrogenase is SEQ ID No. 1 in the sequence list; or
[0033] The nucleotide sequence of the amine dehydrogenase is obtained by performing at least one mutation of the following (1)-(3) on the basis of SEQ ID No. 1 in the sequence list:
[0034] (1) Nucleotides 401-402 mutated from tt to ca or gt;
[0035] (2) nucleotides 896-897 mutated from tt to ca or gt;
[0036] (3) nucleotides 898-900 mutated from agc to ggt, gca, gtt, or ttt;
[0037] Preferably, the mutation is any one of (M1)-(M8) in Table 1 below;
[0038] Most preferably, the nucleotide sequence of the amine dehydrogenase is based on SEQ ID No. 1 in the sequence list, with nucleotides at positions 401-402 mutated from tt to ca, nucleotides at positions 896-897 mutated from tt to ca, and nucleotides at positions 898-900 mutated from agc to ggt.
[0039] As a preferred embodiment, the concentration of the amine dehydrogenase is 20-60 mg / mL, and preferably the concentration of the amine dehydrogenase is 30 mg / mL.
[0040] As a preferred embodiment, the reaction buffer system of the reductive amination is a 2 mol / L NH4Cl / NH4OH solution, with a pH value of 8.5-10.5; preferably a pH value of 10.0; and / or
[0041] The reaction temperature of the reductive amination is 20-60°C, and the reaction time is 3-48h; preferably, the reaction temperature of the reductive amination is 37°C, and the reaction time is 48h.
[0042] As a preferred embodiment, the coenzyme regeneration system uses glucose dehydrogenase in NDA + Under the presence of conditions, it catalyzes the conversion of the substrate glucose into gluconic acid while generating NADH to complete the regeneration of the coenzyme; and / or
[0043] The concentration of the glucose dehydrogenase is 20-60 mg / mL; preferably the concentration of the glucose dehydrogenase is 30 mg / mL; and / or
[0044] The final concentration of glucose is 1-2 mol / L; preferably, the final concentration of glucose is 1 mol / L.
[0045] Compared with the prior art, the beneficial effects of the present invention are as follows:
[0046] (1) The present invention utilizes the biocatalyst amine dehydrogenase to directly reduce and aminize the prochiral ketone into optically pure chiral arylamine, heteroarylamine, and alkylamine in one step under mild conditions, and the only byproduct is water. The process route is simple, the reaction conditions are mild, the yield is high, and it has the advantages of green synthesis such as step economy and atom economy, as well as good stereoselectivity (ee value up to 99%).
[0047] (2) The method of the present invention has a wide range of substrate adaptability, good enantioselectivity, and the yield of various substrates at high concentrations (0.5-2M) is close to 100%, which has important application prospects in the synthesis of drugs, etc. BRIEF DESCRIPTION OF THE DRAWINGS
[0048] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the embodiments of the present invention, they are used to explain the present invention and do not constitute a limitation of the present invention. In the accompanying drawings:
[0049] Figure 1 This is the nuclear magnetic resonance spectrum of the product (R)-4-phenylbutan-2-amine ((R)-4-phenylbutane-2-amine) of No. 3 in Example 2. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0050] Figure 2 This is the nuclear magnetic resonance spectrum of the product (R)-1-phenylhexan-3-amine ((R)-1-phenylhexane-3-amine) of No. 5 in Example 2. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0051] Figure 3This is the nuclear magnetic resonance spectrum of the product (R)-1-(2-bromophenyl)propan-2-amine ((R)-1-(2-bromophenyl)propan-2-amine) of Example 2, No. 9, wherein A is the hydrogen spectrum and B is the carbon spectrum.
[0052] Figure 4 This is the nuclear magnetic resonance spectrum of the product (R)-4-(4-fluorophenyl)butan-2-amine of No. 36 in Example 2. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0053] Figure 5 This is the nuclear magnetic resonance spectrum of the product (R)-1-phenoxypropan-2-amine ((R)-1-phenoxypropane-2-amine) of No. 41 in Example 2, wherein A is the hydrogen spectrum and B is the carbon spectrum.
[0054] Figure 6 This is the nuclear magnetic resonance spectrum of the product (R)-1-(2,6-dimethylphenoxy)propan-2-amine of No. 42 in Example 2. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0055] Figure 7 This is the nuclear magnetic resonance spectrum of the product (R)-4-(4-methoxyphenyl)butan-2-amine of No. 43 in Example 2. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0056] Figure 8 This is the nuclear magnetic resonance spectrum of the product (R)-4-(thiophen-3-yl)butan-2-amine ((R)-4-(thiophen-3-yl)butan-2-amine) of Example 3, No. 11. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0057] Fig. 9 This is the nuclear magnetic resonance spectrum of the product (R)-4-(pyridin-4-yl)butan-2-amine ((R)-4-(pyridin-4-yl)butan-2-amine) of Example 3, No. 12. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0058] Fig.10This is the nuclear magnetic resonance spectrum of the product (R)-4-(benzo[d][1,3]dioxol-5-yl)butan-2-amine ((R)-4-(benzo[d][1,3]dihydroxy-5-yl)butane-2-amine) of Example 3, wherein A is the hydrogen spectrum and B is the carbon spectrum.
[0059] Fig.11 This is the nuclear magnetic resonance spectrum of the product (R)-pentan-2-amine ((R)-pentane-2-amine) of Example 4, No. 1, wherein A is the hydrogen spectrum and B is the carbon spectrum.
[0060] Fig.12 This is the nuclear magnetic resonance spectrum of the product (R)-nonan-2-amine ((R)-nonane-2-amine) of Example 4, No. 5. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0061] Fig.13 This is the nuclear magnetic resonance spectrum of the product (R)6-methylheptan-2-amine ((R)-6-methylheptane-2-amine) of Example 4, No. 15, wherein A is the hydrogen spectrum and B is the carbon spectrum. DETAILED DESCRIPTION
[0062] It should be noted that, in the absence of conflict, the embodiments of the present invention and the features in the embodiments may be combined with each other.
[0063] The following examples are provided for a better understanding of the present invention, but are not intended to limit the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are purchased from conventional biochemical reagent companies unless otherwise specified. The quantitative tests in the following examples are repeated three times, and the results are averaged.
[0064] The preparation method of the chiral arylamine, heteroarylamine and alkylamine of the present invention is as follows:
[0065] The corresponding prochiral ketone is used as raw material, inorganic ammonia is used as amine donor, water is used as main solvent and co-solvent to form solvent system, amine dehydrogenase is used as biocatalyst, NADH is used as coenzyme, coupled glucose (Glu) and glucose dehydrogenase are used as coenzyme regeneration system, and ketone is reduced and aminated into chiral aromatic amine, heteroaromatic amine and alkyl amine.
[0066] The reaction formula is as follows:
[0067]
[0068] in:
[0069] R1 represents any one of aryl, heteroaryl, and alkyl;
[0070] R2 represents any alkyl group having 3 or less carbon atoms;
[0071] When R1 is an alkyl group, it may be the same as or different from R2.
[0072] In some embodiments, the aryl group includes phenyl or benzyl, or alkyl-substituted phenyl or benzyl, or halogen-substituted phenyl or benzyl, or nitro-substituted phenyl or benzyl, or alkylphenyl, wherein the alkyl group has 2-4 carbon atoms.
[0073] In some embodiments, the heteroaryl group includes pyridine, pyrimidine, thiazole, thiophene, furan, and N-substituted indole.
[0074] In some embodiments, the alkyl group in R1 has 1-20 carbon atoms, including methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl and heptyl.
[0075] The present invention has no limitation on the concentration of the substrate, i.e., the prochiral ketone, and the concentration of the substrate is usually 0.5-2 mol / L; for example, the concentration is 0.5 mol / L, 1 mol / L, 1.2 mol / L, 1.5 mol / L, 2 mol / L. Since the enzyme has different tolerance to different substrates, a substrate concentration with a higher TON (turnover number) is preferred.
[0076] In some embodiments, the co-solvent is a deep eutectic solvent (DES) or an organic solvent or an ionic liquid.
[0077] According to some embodiments of the present application, the deep eutectic solvent includes DESs constructed with methyltrioctylammonium chloride as a hydrogen bond acceptor and fatty acids as hydrogen bond donors in a molar ratio of 1:2; the deep eutectic solvents constructed as above can effectively improve the yield of the reaction product.
[0078] According to some embodiments of the present application, the volume ratio of the deep eutectic solvent to the total system is 1-50%, at which time the reaction yield can be improved; preferably, the volume ratio of the deep eutectic solvent to the total system is 20% (v / v), at which time the reaction yield is the highest.
[0079] According to some embodiments of the present application, the fatty acid includes saturated fatty acids and unsaturated fatty acids; the saturated fatty acids are selected from 7-22C fatty acids, such as heptanoic acid, octanoic acid, nonanoic acid and decanoic acid; the unsaturated fatty acids are selected from oleic acid or linolenic acid.
[0080] According to some embodiments of the present application, the organic solvent is a conventional organic solvent, for example, the organic solvent is heptane, ethylene glycol, DMSO, acetonitrile, n-hexane, cyclohexane or methyl tert-butyl ether.
[0081] According to some embodiments of the present application, the ionic liquid is an imidazole ionic liquid, such as 1-butyl-3-methylimidazolium hexafluorophosphate, 1-butyl-3-methylimidazolium di(trifluoromethylsulfonyl)imide, 1-butyl-3-methylimidazolium dinitrile amine salt or 1-butyl-3-methylimidazolium bromide.
[0082] As a preferred embodiment, the co-solvent is a deep eutectic solvent, which is constructed with methyltrioctylammonium chloride as a hydrogen bond acceptor and oleic acid as a hydrogen bond donor in a molar ratio of 1:2; in this case, the yield of the reaction product is the highest.
[0083] In some embodiments, the reaction buffer system of the reductive amination is a 2 mol / L NH4Cl / NH4OH solution (the concentration of NH4Cl is 2 mol / L, and ammonia NH4OH is used to adjust the pH value), and the corresponding product can be obtained when the pH value is 8.5-10.5; the preferred pH value is 10.0, at which the yield is the highest. Among them, NH4Cl / NH4OH provides inorganic ammonia as an amine donor, and water is used as the main solvent in the reaction system.
[0084] In some embodiments, the reaction temperature of the reductive amination is 20-60° C., and the reaction time is 3-48 h.
[0085] As a preferred solution, the reaction temperature of the reductive amination is 37° C. and the reaction time is 48 h, at which time the yield is the highest.
[0086] In some embodiments, the coenzyme regeneration system uses glucose dehydrogenase (GDH) in DNA + Under the presence of certain conditions, it catalyzes the conversion of the substrate glucose into gluconic acid while generating NADH to complete the regeneration of the coenzyme.
[0087] In some embodiments, the concentration of glucose dehydrogenase is 20-60 mg / mL, and a product with high yield can be prepared within this range; preferably, the concentration of glucose dehydrogenase is 30 mg / mL, at which time the yield of the obtained product is the highest.
[0088] In some embodiments, the final concentration of glucose is 1-2 mol / L, and products with high yields can be prepared within this range; preferably, the final concentration of glucose is 1 mol / L, at which time the yield of the obtained product is the highest.
[0089] In some embodiments, the amine dehydrogenase is a natural amino acid dehydrogenase derived from Caldalkalibacillus thermarum obtained by protein engineering.
[0090] The nucleotide sequence of the natural amino acid dehydrogenase from Caldalkalibacillus thermarum is as follows (SEQ ID No. 1):
[0091]
[0092] The amino acid sequence of the natural amino acid dehydrogenase from Caldalkalibacillus thermarum is as follows (SEQ ID No. 2):
[0093]
[0094] Different forms of mutations were performed on the three important amino acid sites of the natural amino acid dehydrogenase from Caldalkalibacillus thermarum to obtain different mutant proteins M1-M8. The specific amino acid mutation sites and the corresponding nucleotide sequences of the mutants are shown in Table 1.
[0095] Table 1 Amino acid mutation sites and nucleotide sequences corresponding to the mutants
[0096]
[0097]
[0098] The above-mentioned natural amino acid dehydrogenase and mutant proteins M1-M8 all have catalytic activity and good stereoselectivity.
[0099] According to some embodiments of the present application, the method for constructing the genetically engineered bacteria of amine dehydrogenase is as follows: synthesizing the nucleotide sequence shown in SEQ ID NO: 1 and the nucleotide sequence encoding mutants M1-M8 (see Table 1), respectively, adding corresponding restriction sites at both ends of the gene, respectively, and constructing the synthesized genes into corresponding expression vectors, and then transferring the expression vectors into recipient bacteria, that is, obtaining the genetically engineered bacteria AmDH-M0 (corresponding to the nucleotide sequence shown in SEQ ID NO: 1), AmDH-M1 to AmDH-M8 (corresponding to mutants M1 to mutant M8 in sequence); and fermenting and culturing the genetically engineered bacteria to achieve efficient heterologous expression of amine dehydrogenase.
[0100] According to some embodiments of the present application, the expression vector is a pET series plasmid, and the restriction enzyme cutting sites are EcoRI and XhoI restriction enzyme cutting sites.
[0101] According to some embodiments of the present application, the recipient bacteria is the Escherichia coli BL21 series, and the recipient bacteria can efficiently express exogenous genes.
[0102] According to some embodiments of the present application, in the present invention, the transformant obtained by transforming the host with the plasmid can grow and produce the amine dehydrogenase of the present invention based on known information. For example, when fermenting genetically engineered bacteria, the seed culture medium uses LB culture medium, and the expanded culture uses TB culture medium.
[0103] As a preferred embodiment, the amine dehydrogenase of the present invention can be the bacterial cells of AmDH-M0 to AmDH-M8 obtained by centrifuging the culture medium of the above-mentioned amine dehydrogenase genetically engineered bacteria, or can be the extracts, broken liquids obtained from the bacterial cells of AmDH-M0 to AmDH-M8, or the refined enzymes obtained after purification by a protein purifier, all of which have catalytic activity towards aromatic ketones, heteroaromatic ketones, and alkyl ketones, among which AmDH-5 has the highest catalytic activity.
[0104] According to some embodiments of the present application, the concentration of the amine dehydrogenase is 20-60 mg / mL, and a product with high yield can be obtained within this range; preferably, the concentration of the amine dehydrogenase is 30 mg / mL, at which time the yield of the product obtained is the highest.
[0105] According to some embodiments of the present application, after the ketone is reductively aminized to a chiral arylamine, heteroarylamine or alkylamine, the mixture is extracted with ethyl acetate, the organic layer is collected, the organic layer is dried, and then chromatographic separation is performed.
[0106] As a preferred embodiment, the chromatographic separation is performed using a silica gel column, wherein the volume ratio of ethyl acetate:methanol is 99:1-90:10.
[0107] The present invention will be further described below with reference to embodiments:
[0108] Example 1 Asymmetric Synthesis of (R)-1-Phenyl-2-Propanamine
[0109] Synthesis route:
[0110]
[0111] The substrate phenylacetone (5 mmol), NAD +(0.005mmol), 4mL of 2mol / LNH4Cl / NH4OH solution (NH4Cl final concentration is 2mol / L, and then NH4OH is used to adjust pH to 10.0), AmDH-M5 cells (30mg / mL), glucose dehydrogenase (GDH) cells (30mg / mL), glucose (5mmol), and 1mL of deep eutectic solvent (DES, the molar ratio of quaternary ammonium salt to oleic acid is 1:2, and the volume ratio of DES in the reaction system is 20%) were added to a 10mL pressure tube. The reaction mixture was stirred at 37°C for 48h. After the reaction was completed, the mixture was extracted with ethyl acetate (3×5mL). Ethyl acetate can extract both the substrate and the product in the reaction system into the organic phase layer. The organic layer was first dried with Na2SO4 and then separated by silica gel column chromatography (first using 50mL of a mixture of ethyl acetate and ethanol (the volume ratio of the two is 99:1), and then using 150mL of a mixture of ethyl acetate and ethanol (the volume ratio of the two is 90:10)). Take another 1 mL of ethyl acetate extract, add 100 μL of acetic anhydride, vortex for 10 s, and use for gas chromatography detection.
[0112] The yield, configuration and ee value of the asymmetric reduction product were determined by gas chromatography, and the chromatographic conditions were: Agilent J&W CP-Chiralsil-DEXCB column (25m×0.32mm×0.25μm), column temperature program: starting temperature 100°C, heating at a rate of 5°C / min to 200°C, and retaining at 200°C for 5min. (R)-1-phenyl-2-propylamine was obtained with a yield of 99% and an ee value of 99%.
[0113] When the parameters in the above preparation process are different, the yields of the prepared products are different, and the specific results are shown in Table 1. In Table 1, the molar ratio of methyl trioctyl ammonium chloride and different fatty acids in the deep eutectic solvent is 1:2.
[0114] Table 1
[0115]
[0116]
[0117] According to the results in Table 1, 2 mol / L NH4Cl / NH4OH with a pH of 10.0 was finally selected as the reaction solution, the substrate concentration was 1 mol / L, 20% by volume methyltrioctylammonium chloride-oleic acid was used as a cosolvent, AmDH-M5 was used as a catalyst, the catalyst concentration was 30 mg / mL, the GDH cell concentration was 30 mg / mL, the final glucose concentration was 1 mol / L, and the reaction temperature was 37°C as the optimal reaction conditions.
[0118] The following examples were all carried out under the optimal reaction conditions obtained above.
[0119] Example 2 Synthesis of Chiral Arylamines
[0120] Different substrates were selected and the optimal reaction conditions screened in Example 1 were used to carry out the reaction to obtain a series of chiral aromatic amines. Detailed information on different substrates and products is shown in Table 2.
[0121] Table 2 A series of chiral aromatic amines prepared from different substrates
[0122]
[0123]
[0124] Figure 1 This is the nuclear magnetic resonance spectrum of the product (R)-4-phenylbutan-2-amine ((R)-4-phenylbutane-2-amine) of No. 3 in Example 2. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0125] Figure 2 This is the nuclear magnetic resonance spectrum of the product (R)-1-phenylhexan-3-amine ((R)-1-phenylhexane-3-amine) of No. 5 in Example 2. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0126] Figure 3 This is the nuclear magnetic resonance spectrum of the product (R)-1-(2-bromophenyl)propan-2-amine ((R)-1-(2-bromophenyl)propan-2-amine) of Example 2, No. 9, wherein A is the hydrogen spectrum and B is the carbon spectrum.
[0127] Figure 4 This is the nuclear magnetic resonance spectrum of the product (R)-4-(4-fluorophenyl)butan-2-amine of No. 36 in Example 2. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0128] Figure 5 This is the nuclear magnetic resonance spectrum of the product (R)-1-phenoxypropan-2-amine ((R)-1-phenoxypropane-2-amine) of No. 41 in Example 2, wherein A is the hydrogen spectrum and B is the carbon spectrum.
[0129] Figure 6 This is the nuclear magnetic resonance spectrum of the product (R)-1-(2,6-dimethylphenoxy)propan-2-amine of No. 42 in Example 2. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0130] Figure 7This is the nuclear magnetic resonance spectrum of the product (R)-4-(4-methoxyphenyl)butan-2-amine of No. 43 in Example 2. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0131] Example 3 Synthesis of Chiral Heteroarylamines
[0132] Different substrates were selected and the optimal reaction conditions screened in Example 1 were used to react to obtain a series of chiral heteroaryl amines. Detailed information on different substrates and products is shown in Table 3.
[0133] Table 3 A series of chiral heteroaryl amines prepared from different substrates
[0134]
[0135]
[0136] Figure 8 This is the nuclear magnetic resonance spectrum of the product (R)-4-(thiophen-3-yl)butan-2-amine ((R)-4-(thiophen-3-yl)butan-2-amine) of Example 3, No. 11. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0137] Fig. 9 This is the nuclear magnetic resonance spectrum of the product (R)-4-(pyridin-4-yl)butan-2-amine ((R)-4-(pyridin-4-yl)butan-2-amine) of Example 3, No. 12. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0138] Fig.10 This is the nuclear magnetic resonance spectrum of the product (R)-4-(benzo[d][1,3]dioxol-5-yl)butan-2-amine ((R)-4-(benzo[d][1,3]dihydroxy-5-yl)butane-2-amine) of Example 3, wherein A is the hydrogen spectrum and B is the carbon spectrum.
[0139] Example 4 Synthesis of Chiral Alkylamine
[0140] Different substrates were selected and the optimal reaction conditions screened in Example 1 were used to react to obtain a series of chiral alkylamines. Detailed information on different substrates and products is shown in Table 4.
[0141] Table 4 A series of chiral alkylamines prepared from different substrates
[0142]
[0143]
[0144] Fig.11 This is the nuclear magnetic resonance spectrum of the product (R)-pentan-2-amine ((R)-pentane-2-amine) of Example 4, No. 1, wherein A is the hydrogen spectrum and B is the carbon spectrum.
[0145] Fig.12 This is the nuclear magnetic resonance spectrum of the product (R)-nonan-2-amine ((R)-nonane-2-amine) of Example 4, No. 5. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0146] Fig.13 This is the nuclear magnetic resonance spectrum of the product (R)6-methylheptan-2-amine ((R)-6-methylheptane-2-amine) (R)-6-methylpentan-2-amine ((R)-6-methylpentane-2-amine) of Example 4, No. 15. Wherein, A is the hydrogen spectrum and B is the carbon spectrum.
[0147] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A method for preparing chiral arylamines, heteroarylamines and alkylamines, characterized in that: The following steps are involved: The corresponding prochiral ketone is used as a raw material, inorganic ammonia is used as an amine donor, water is used as a main solvent and a cosolvent is used to form a solvent system, amine dehydrogenase is used as a biocatalyst, NADH is used as a coenzyme, and coupled glucose and glucose dehydrogenase are used as a coenzyme regeneration system to reduce and aminize the ketone into chiral arylamine, heteroarylamine, and alkylamine. The reaction formula is as follows: in: R1 represents any one of aryl, heteroaryl, and alkyl; R2 represents any alkyl group having 3 or less carbon atoms; When R1 is an alkyl group, it is the same as or different from R2; The co-solvent is a deep eutectic solvent, an organic solvent or an ionic liquid.
2. The preparation method according to claim 1, characterized in that: The aryl group includes phenyl or benzyl, or alkyl-substituted phenyl or benzyl, or halogen-substituted phenyl or benzyl, or nitro-substituted phenyl or benzyl, or alkylphenyl, wherein the alkyl group in the alkylphenyl has 2-4 carbon atoms; The heteroaryl groups include pyridine, pyrimidine, thiazole, thiophene, furan, and N-substituted indole; The carbon number of the alkyl group in R1 is 1-20.
3. The preparation method according to claim 1, characterized in that: The concentration of the prochiral ketone is 0.5-2 mol / L.
4. The preparation method according to any one of claims 1 to 3, characterized in that: The deep eutectic solvent includes DESs constructed with methyl trioctyl ammonium chloride and fatty acid in a molar ratio of 1:(0.5-2); The organic solvent is selected from heptane, ethylene glycol, DMSO, acetonitrile, n-hexane, cyclohexane or methyl tert-butyl ether; The ionic liquid is an imidazole ionic liquid, preferably 1-butyl-3-methylimidazolium hexafluorophosphate, 1-butyl-3-methylimidazolium di(trifluoromethylsulfonyl)imide, 1-butyl-3-methylimidazolium dinitrile amine salt or 1-butyl-3-methylimidazolium bromide; Preferably, the fatty acids include saturated fatty acids and unsaturated fatty acids; the saturated fatty acids are selected from 7-22C fatty acids, such as heptanoic acid, octanoic acid, nonanoic acid and decanoic acid; the unsaturated fatty acids are selected from oleic acid or linolenic acid.
5. The preparation method according to claim 4, characterized in that: The concentration of the deep eutectic solvent is 1-50% (v / v); preferably the concentration of the deep eutectic solvent is 20% (v / v); and / or The deep eutectic solvent is constructed from methyltrioctylammonium chloride and oleic acid in a molar ratio of 1:
2.
6. The preparation method according to claim 1, characterized in that: The amino acid sequence of the amine dehydrogenase is SEQ ID No. 2 in the sequence list; or The amino acid sequence of the amine dehydrogenase is mutated based on SEQ ID No. 2 in the sequence list, and the mutation includes at least one of the following (1)-(3): (1) Position 134 mutated from V to A or G; (2) position 299 mutated from V to A or G; (3) position 300 mutated from S to G, A, V, or F; Preferably, the mutation is any one of the following (M1)-(M8): (M1) the amino acid residue at position 134 of SEQ ID NO.2 was mutated from V to A; (M2) amino acid residue 134 of SEQ ID NO.2 mutated from V to G; (M3) The amino acid residue at position 134 of SEQ ID NO.2 is mutated from V to A; and the amino acid residue at position 299 is mutated from V to A; (M4) The amino acid residue at position 134 of SEQ ID NO.2 is mutated from V to A; and the amino acid residue at position 299 is mutated from V to G; (M5) The amino acid residue at position 134 of SEQ ID NO.2 is mutated from V to A; the amino acid residue at position 299 is mutated from V to A; and the amino acid residue at position 300 is mutated from S to G; (M6) The amino acid residue at position 134 of SEQ ID NO.2 is mutated from V to A; the amino acid residue at position 299 is mutated from V to A; and the amino acid residue at position 300 is mutated from S to A; (M7) The amino acid residue at position 134 of SEQ ID NO.2 is mutated from V to A; the amino acid residue at position 299 is mutated from V to A; and the amino acid residue at position 300 is mutated from S to V; (M8) The amino acid residue at position 134 of SEQ ID NO.2 mutated from V to A; the amino acid residue at position 299 mutated from V to A; and the amino acid residue at position 300 mutated from S to F. Most preferably, the amino acid sequence of the amine dehydrogenase is based on SEQ ID No. 2 in the sequence listing, with position 134 mutated from V to A, and position 299 mutated from V to A; and the amino acid residue at position 300 mutated from S to G.
7. The preparation method according to claim 6, characterized in that: The nucleotide sequence of the amine dehydrogenase is SEQ ID No. 1 in the sequence list; or The nucleotide sequence of the amine dehydrogenase is obtained by performing at least one mutation of the following (1)-(3) on the basis of SEQ ID No. 1 in the sequence list: (1) Nucleotides 401-402 mutated from tt to ca or gt; (2) nucleotides 896-897 mutated from tt to ca or gt; (3) nucleotides 898-900 mutated from agc to ggt, gca, gtt, or ttt; Preferably, the mutation is any one of the following (1)-(8): (1) The nucleotides at positions 401-402 of SEQ ID NO.1 were mutated from tt to ca; (2) The nucleotides at positions 401-402 of SEQ ID NO.1 were mutated from tt to gt; (3) The nucleotides at positions 401-402 of SEQ ID NO.1 were mutated from tt to ca; and the nucleotides at positions 896-897 were mutated from tt to ca; (4) The nucleotides at positions 401-402 of SEQ ID NO.1 were mutated from tt to ca; and the nucleotide at position 896 was mutated from t to g; (5) The nucleotides at positions 401-402 of SEQ ID NO.1 mutated from tt to ca; and the nucleotides at positions 896-897 mutated from tt to ca; and the nucleotides at positions 898-900 mutated from agc to ggt; (6) The nucleotides at positions 401-402 of SEQ ID NO.1 mutated from tt to ca; and the nucleotides at positions 896-897 mutated from tt to ca; and the nucleotides at positions 898-900 mutated from agc to gca; (7) The nucleotides at positions 401-402 of SEQ ID NO.1 mutated from tt to ca; and the nucleotides at positions 896-897 mutated from tt to ca; and the nucleotides at positions 898-900 mutated from agc to gtt; (8) The nucleotides at positions 401-402 of SEQ ID NO.1 were mutated from tt to ca; the nucleotides at positions 896-897 were mutated from tt to ca; and the nucleotides at positions 898-900 were mutated from agc to ttt; Most preferably, the nucleotide sequence of the amine dehydrogenase is based on SEQ ID No. 1 in the sequence list, with nucleotides at positions 401-402 mutated from tt to ca; nucleotides at positions 896-897 mutated from tt to ca; and nucleotides at positions 898-900 mutated from agc to ggt.
8. The preparation method according to any one of claims 1 to 7, characterized in that: The concentration of the amine dehydrogenase is 20-60 mg / mL, and preferably the concentration of the amine dehydrogenase is 30 mg / mL.
9. The preparation method according to any one of claims 1 to 3, characterized in that: The reaction buffer system of the reductive amination is a 2 mol / L NH4Cl / NH4OH solution, with a pH value of 8.5-10.5; preferably a pH value of 10.0; and / or The reaction temperature of the reductive amination is 20-60°C, and the reaction time is 3-48h; preferably, the reaction temperature of the reductive amination is 37°C, and the reaction time is 48h.
10. The preparation method according to any one of claims 1 to 3, characterized in that: The coenzyme regeneration system uses glucose dehydrogenase in NDA + Under the presence of conditions, it catalyzes the conversion of substrate glucose into gluconic acid while generating NADH to complete the regeneration of the coenzyme; and / or The concentration of the glucose dehydrogenase is 20-60 mg / mL; preferably the concentration of the glucose dehydrogenase is 30 mg / mL; and / or The final concentration of glucose is 1-2 mol / L; preferably, the final concentration of glucose is 1 mol / L.
Citation Information
Cited By
Synthesis method for chiral amine
WO2026081317A1
